<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02989480</url>
  </required_header>
  <id_info>
    <org_study_id>3/072/14</org_study_id>
    <nct_id>NCT02989480</nct_id>
  </id_info>
  <brief_title>PET-detected Myocardial Inflammation is a Characteristic of Cardiac Sarcoid But Not of ARVC</brief_title>
  <official_title>PET-detected Myocardial Inflammation is a Characteristic of Cardiac Sarcoid But Not of ARVC - a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aberdeen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Grampian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aberdeen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare condition in which the heart&#xD;
      muscle cells especially of the main pumping chamber (the 'ventricle') is replaced by fat and&#xD;
      scar tissue. Sarcoidosis is a condition that can affect many organs but when it affects the&#xD;
      heart patches of inflammation can result in scarring, especially of the ventricles. Both&#xD;
      conditions can cause dangerous heart rhythms and sudden death. Sarcoidosis can be treated&#xD;
      with inflammation suppressing treatment (steroids), as well as pacemakers and implantable&#xD;
      defibrillators which shock the heart back to normal rhythm. ARVC is usually treated with&#xD;
      implantable defibrillators. The diagnosis of either condition can be difficult and indeed&#xD;
      distinguishing the two can be extremely challenging. Increasingly nuclear scans (PET) are&#xD;
      used to identify inflammation in the heart in patients suspected of having cardiac sarcoid.&#xD;
      It is not known whether patients with ARVC have abnormal PET scans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare inherited condition&#xD;
      characterised pathologically by fibro-fatty replacement of myocytes usually (but not&#xD;
      exclusively) within the right ventricle. The clinical consequences of this process are&#xD;
      usually re-entrant ventricular arrhythmias which may be fatal and ARVC consequently is the&#xD;
      third most common cause of sudden cardiac death in the young. Diagnosis involves imaging,&#xD;
      electrocardiography, myocardial biopsy and genetic testing. Task Force criteria for the&#xD;
      diagnosis have been established. Nevertheless the condition can be difficult to diagnose (or&#xD;
      exclude), especially in less advanced disease, a common scenario in individuals with a family&#xD;
      member suffering from the condition. To complicate the situation further, we and others have&#xD;
      published recent reports suggesting that other infiltrative conditions within the heart&#xD;
      especially sarcoidosis, may fulfil Task Force criteria, leading to a false positive&#xD;
      diagnosis. This is a particular concern since the natural history and treatment options for&#xD;
      these conditions are very different.&#xD;
&#xD;
      Sarcoidosis is a granulomatous disorder of unknown cause, predominantly affecting the lungs,&#xD;
      reticuloendothelial systems and skin. Cardiac involvement at autopsy is found in up to 25% of&#xD;
      affected individuals although clinical manifestations are only present in approximately 5%.&#xD;
      Isolated cardiac sarcoidosis, without manifestations in other systems is rare. The&#xD;
      non-caseating granulomas frequently infiltrate left ventricular &amp; septal myocardium although&#xD;
      right ventricular involvement also occurs. Granulomas and resulting scar formation can cause&#xD;
      conduction disturbances, cardiac failure and ventricular arrhythmias. Sudden death is not&#xD;
      uncommon. Myocardial biopsy confirms the diagnosis but because of the patchy nature of the&#xD;
      granulomatous process, the test is only positive in 50% of the affected individuals. Other&#xD;
      investigations used to help make or support the diagnosis include echocardiography, MRI,&#xD;
      electrocardiography, PET, and corroborating evidence from high resolution CT chest and skin&#xD;
      biopsy. However, imaging findings may lack specificity for a precise aetiology. Cardiac MRI&#xD;
      identifies areas of myocardial scar or fibrosis, which is the final step in the disease&#xD;
      process. Although patterns of fibrosis have been well described in ARVC and cardiac&#xD;
      sarcoidosis, significant overlap exists between these two diseases with regard to the exact&#xD;
      location of fibrosis: for example ARVC can affect either or both ventricles. Typically,&#xD;
      although affecting predominantly the RV, in advanced stages there is also a well described&#xD;
      pattern of mid-wall patchy fibrosis in the basal infero-lateral wall of the left ventricle&#xD;
      and sometimes in the inter-ventricular septum. Conversely, sarcoidosis typically affects the&#xD;
      LV, and when fibrosis is found, the location is in the septal or infero-lateral territories.&#xD;
      In sarcoid, RV enlargement can occur either due to granulomatous involvement within the RV&#xD;
      myocardium, or secondary to the pulmonary hypertension associated with lung involvement.&#xD;
      Cases of sarcoidosis where the RV is involved may be more difficult to diagnose: The RV&#xD;
      enlargement and reduction in function overlap significantly with the Task Force Criteria for&#xD;
      the CMR diagnosis of ARVC, furthermore, the pattern of late gadolinium enhancement is not&#xD;
      sufficiently specific to guide the diagnosis to either ARVC or Cardiac Sarcoid with RV&#xD;
      involvement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial inflammation or fibrosis by cardiac MRI and PET CT</measure>
    <time_frame>Three hours</time_frame>
    <description>Cardiac MRI and PET CT</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Arrhythmogenic Right Ventricular Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Sarcoidosis</arm_group_label>
    <description>Patients with cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and Welfare criteria will be included. All patients will have histologically proven sarcoidosis (cardiac biopsy not mandatory) and no other potential cardiac disease. They will have no family history of cardiomyopathy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arrhythmogenic RV cardiomyopathy</arm_group_label>
    <description>Patients with ARVC diagnosed according to the Task Force criteria with in addition either a positive family history for the condition or harbour a known pathological mutation associated with it.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET CT</intervention_name>
    <description>PET CT scans</description>
    <arm_group_label>Arrhythmogenic RV cardiomyopathy</arm_group_label>
    <arm_group_label>Sarcoidosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Cardiac MRI</description>
    <arm_group_label>Arrhythmogenic RV cardiomyopathy</arm_group_label>
    <arm_group_label>Sarcoidosis</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      ACE inhibitors and CRP will be measured.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Twenty patients from the age of 18-70 will be studied. We will include 10 patients with&#xD;
        cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and Welfare&#xD;
        criteria. All patients will have histologically proven sarcoidosis (cardiac biopsy not&#xD;
        mandatory) and no other potential cardiac disease. They will have no family history of&#xD;
        cardiomyopathy. We will also study 10 patients with ARVC diagnosed according to the Task&#xD;
        Force criteria with in addition either a positive family history for the condition or&#xD;
        harbour a known pathological mutation associated with it.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Twenty patients from the age of 18-70 will be studied. We will include 10 patients&#xD;
             with cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and&#xD;
             Welfare criteria. All patients will have histologically proven sarcoidosis (cardiac&#xD;
             biopsy not mandatory) and no other potential cardiac disease. They will have no family&#xD;
             history of cardiomyopathy. We will also study 10 patients with ARVC diagnosed&#xD;
             according to the Task Force criteria with in addition either a positive family history&#xD;
             for the condition or harbour a known pathological mutation associated with it.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients outside the age limit defined above and those who do not fulfil our inclusion&#xD;
             criteria for either cardiac sarcoidosis or ARVC will be excluded.&#xD;
&#xD;
          -  unwillingness to participate&#xD;
&#xD;
          -  patients with any contraindication to MR scanning&#xD;
&#xD;
          -  pregnant or breast feeding women&#xD;
&#xD;
          -  diabetes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Broadhurst, Consultant</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Grampian</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Broadhurst, Consultant</last_name>
    <phone>01224559308</phone>
    <email>paul.broadhurst@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana Dawson, Consultant</last_name>
    <phone>01224437969</phone>
    <email>dana.dawson@abdn.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Aberdeenshire</state>
        <zip>AB25 2ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Broadhurst, Consultant</last_name>
      <phone>01224559308</phone>
      <email>paul.broadhurst@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Dana Dawson, Consultant</last_name>
      <phone>01224437969</phone>
      <email>dana.dawson@abdn.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010 Apr 6;121(13):1533-41. doi: 10.1161/CIRCULATIONAHA.108.840827. Epub 2010 Feb 19.</citation>
    <PMID>20172911</PMID>
  </reference>
  <reference>
    <citation>Dempsey OJ, Paterson EW, Kerr KM, Denison AR. Sarcoidosis. BMJ. 2009 Aug 28;339:b3206. doi: 10.1136/bmj.b3206. No abstract available.</citation>
    <PMID>19717499</PMID>
  </reference>
  <reference>
    <citation>Mohsen A, Panday M, Wetherold S, Jimenez A. Cardiac sarcoidosis mimicking arrhythmogenic right ventricular dysplasia with high defibrillation threshold requiring subcutaneous shocking coil implantation. Heart Lung Circ. 2012 Jan;21(1):46-9. doi: 10.1016/j.hlc.2011.08.013. Epub 2011 Oct 6.</citation>
    <PMID>21982156</PMID>
  </reference>
  <reference>
    <citation>Sen-Chowdhry S, Morgan RD, Chambers JC, McKenna WJ. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu Rev Med. 2010;61:233-53. doi: 10.1146/annurev.med.052208.130419.</citation>
    <PMID>20059337</PMID>
  </reference>
  <reference>
    <citation>Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009 Nov 17;120(20):1969-77. doi: 10.1161/CIRCULATIONAHA.109.851352. Epub 2009 Nov 2.</citation>
    <PMID>19884472</PMID>
  </reference>
  <reference>
    <citation>Lobert P, Brown RK, Dvorak RA, Corbett JR, Kazerooni EA, Wong KK. Spectrum of physiological and pathological cardiac and pericardial uptake of FDG in oncology PET-CT. Clin Radiol. 2013 Jan;68(1):e59-71. doi: 10.1016/j.crad.2012.09.007. Epub 2012 Nov 22.</citation>
    <PMID>23177651</PMID>
  </reference>
  <reference>
    <citation>Campian ME, Verberne HJ, Hardziyenka M, de Groot EA, van Moerkerken AF, van Eck-Smit BL, Tan HL. Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2079-85. doi: 10.1007/s00259-010-1525-y. Epub 2010 Jul 6.</citation>
    <PMID>20603720</PMID>
  </reference>
  <reference>
    <citation>Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol. 2009 May;20(5):578-83. doi: 10.1111/j.1540-8167.2008.01417.x. Epub 2009 Jan 9.</citation>
    <PMID>19175448</PMID>
  </reference>
  <reference>
    <citation>Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008 Feb;190(2):W151-6. doi: 10.2214/AJR.07.2409.</citation>
    <PMID>18212199</PMID>
  </reference>
  <reference>
    <citation>Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009 Sep-Oct;16(5):801-10. doi: 10.1007/s12350-009-9110-0. Epub 2009 Jun 23.</citation>
    <PMID>19548047</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>December 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02989480
org study id: 3/072/14
nct id: NCT02989480
lead sponsor: 
collaborator: 
has dmc: No
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare condition in which the heart
      muscle cells especially of the main pumping chamber (the 'ventricle') is replaced by fat and
      scar tissue. Sarcoidosis is a condition that can affect many organs but when it affects the
      heart patches of inflammation can result in scarring, especially of the ventricles. Both
      conditions can cause dangerous heart rhythms and sudden death. Sarcoidosis can be treated
      with inflammation suppressing treatment (steroids), as well as pacemakers and implantable
      defibrillators which shock the heart back to normal rhythm. ARVC is usually treated with
      implantable defibrillators. The diagnosis of either condition can be difficult and indeed
      distinguishing the two can be extremely challenging. Increasingly nuclear scans (PET) are
      used to identify inflammation in the heart in patients suspected of having cardiac sarcoid.
      It is not known whether patients with ARVC have abnormal PET scans.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare inherited condition
      characterised pathologically by fibro-fatty replacement of myocytes usually (but not
      exclusively) within the right ventricle. The clinical consequences of this process are
      usually re-entrant ventricular arrhythmias which may be fatal and ARVC consequently is the
      third most common cause of sudden cardiac death in the young. Diagnosis involves imaging,
      electrocardiography, myocardial biopsy and genetic testing. Task Force criteria for the
      diagnosis have been established. Nevertheless the condition can be difficult to diagnose (or
      exclude), especially in less advanced disease, a common scenario in individuals with a family
      member suffering from the condition. To complicate the situation further, we and others have
      published recent reports suggesting that other infiltrative conditions within the heart
      especially sarcoidosis, may fulfil Task Force criteria, leading to a false positive
      diagnosis. This is a particular concern since the natural history and treatment options for
      these conditions are very different.

      Sarcoidosis is a granulomatous disorder of unknown cause, predominantly affecting the lungs,
      reticuloendothelial systems and skin. Cardiac involvement at autopsy is found in up to 25% of
      affected individuals although clinical manifestations are only present in approximately 5%.
      Isolated cardiac sarcoidosis, without manifestations in other systems is rare. The
      non-caseating granulomas frequently infiltrate left ventricular & septal myocardium although
      right ventricular involvement also occurs. Granulomas and resulting scar formation can cause
      conduction disturbances, cardiac failure and ventricular arrhythmias. Sudden death is not
      uncommon. Myocardial biopsy confirms the diagnosis but because of the patchy nature of the
      granulomatous process, the test is only positive in 50% of the affected individuals. Other
      investigations used to help make or support the diagnosis include echocardiography, MRI,
      electrocardiography, PET, and corroborating evidence from high resolution CT chest and skin
      biopsy. However, imaging findings may lack specificity for a precise aetiology. Cardiac MRI
      identifies areas of myocardial scar or fibrosis, which is the final step in the disease
      process. Although patterns of fibrosis have been well described in ARVC and cardiac
      sarcoidosis, significant overlap exists between these two diseases with regard to the exact
      location of fibrosis: for example ARVC can affect either or both ventricles. Typically,
      although affecting predominantly the RV, in advanced stages there is also a well described
      pattern of mid-wall patchy fibrosis in the basal infero-lateral wall of the left ventricle
      and sometimes in the inter-ventricular septum. Conversely, sarcoidosis typically affects the
      LV, and when fibrosis is found, the location is in the septal or infero-lateral territories.
      In sarcoid, RV enlargement can occur either due to granulomatous involvement within the RV
      myocardium, or secondary to the pulmonary hypertension associated with lung involvement.
      Cases of sarcoidosis where the RV is involved may be more difficult to diagnose: The RV
      enlargement and reduction in function overlap significantly with the Task Force Criteria for
      the CMR diagnosis of ARVC, furthermore, the pattern of late gadolinium enhancement is not
      sufficiently specific to guide the diagnosis to either ARVC or Cardiac Sarcoid with RV
      involvement.
observational model: Other
time perspective: Prospective
measure: Myocardial inflammation or fibrosis by cardiac MRI and PET CT
time frame: Three hours
description: Cardiac MRI and PET CT
arm group label: Sarcoidosis
description: Patients with cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and Welfare criteria will be included. All patients will have histologically proven sarcoidosis (cardiac biopsy not mandatory) and no other potential cardiac disease. They will have no family history of cardiomyopathy.
arm group label: Arrhythmogenic RV cardiomyopathy
description: Patients with ARVC diagnosed according to the Task Force criteria with in addition either a positive family history for the condition or harbour a known pathological mutation associated with it.
intervention type: Radiation
intervention name: PET CT
description: PET CT scans
arm group label: Arrhythmogenic RV cardiomyopathy
arm group label: Sarcoidosis
intervention type: Other
intervention name: Cardiac MRI
description: Cardiac MRI
arm group label: Arrhythmogenic RV cardiomyopathy
arm group label: Sarcoidosis
ACE inhibitors and CRP will be measured.
study pop: 
sampling method: Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: No
last name: Paul Broadhurst, Consultant
role: Principal Investigator
affiliation: NHS Grampian
last name: Paul Broadhurst, Consultant
phone: 01224559308
email: paul.broadhurst@nhs.net
last name: Dana Dawson, Consultant
phone: 01224437969
email: dana.dawson@abdn.ac.uk
facility: 
status: Recruiting
contact: 
contact backup: 
country: United Kingdom
citation: Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DM, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010 Apr 6;121(13):1533-41. doi: 10.1161/CIRCULATIONAHA.108.840827. Epub 2010 Feb 19.
PMID: 20172911
citation: Dempsey OJ, Paterson EW, Kerr KM, Denison AR. Sarcoidosis. BMJ. 2009 Aug 28;339:b3206. doi: 10.1136/bmj.b3206. No abstract available.
PMID: 19717499
citation: Mohsen A, Panday M, Wetherold S, Jimenez A. Cardiac sarcoidosis mimicking arrhythmogenic right ventricular dysplasia with high defibrillation threshold requiring subcutaneous shocking coil implantation. Heart Lung Circ. 2012 Jan;21(1):46-9. doi: 10.1016/j.hlc.2011.08.013. Epub 2011 Oct 6.
PMID: 21982156
citation: Sen-Chowdhry S, Morgan RD, Chambers JC, McKenna WJ. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu Rev Med. 2010;61:233-53. doi: 10.1146/annurev.med.052208.130419.
PMID: 20059337
citation: Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009 Nov 17;120(20):1969-77. doi: 10.1161/CIRCULATIONAHA.109.851352. Epub 2009 Nov 2.
PMID: 19884472
citation: Lobert P, Brown RK, Dvorak RA, Corbett JR, Kazerooni EA, Wong KK. Spectrum of physiological and pathological cardiac and pericardial uptake of FDG in oncology PET-CT. Clin Radiol. 2013 Jan;68(1):e59-71. doi: 10.1016/j.crad.2012.09.007. Epub 2012 Nov 22.
PMID: 23177651
citation: Campian ME, Verberne HJ, Hardziyenka M, de Groot EA, van Moerkerken AF, van Eck-Smit BL, Tan HL. Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2079-85. doi: 10.1007/s00259-010-1525-y. Epub 2010 Jul 6.
PMID: 20603720
citation: Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol. 2009 May;20(5):578-83. doi: 10.1111/j.1540-8167.2008.01417.x. Epub 2009 Jan 9.
PMID: 19175448
citation: Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008 Feb;190(2):W151-6. doi: 10.2214/AJR.07.2409.
PMID: 18212199
citation: Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol. 2009 Sep-Oct;16(5):801-10. doi: 10.1007/s12350-009-9110-0. Epub 2009 Jun 23.
PMID: 19548047
responsible party type: Sponsor
mesh term: Cardiomyopathies
mesh term: Arrhythmogenic Right Ventricular Dysplasia
mesh term: Myocarditis
mesh term: Sarcoidosis
mesh term: Inflammation
sharing ipd: No